STREAMING NOW: Watch Now

FDA concludes examination of Parkinson's drug

The Food and Drug Administration announced Thursday it had not identified any "new or unexpected safety find...

Posted: Sep 21, 2018 10:50 AM
Updated: Sep 21, 2018 10:50 AM

The Food and Drug Administration announced Thursday it had not identified any "new or unexpected safety findings" related to a drug used to treat psychosis in Parkinson's patients, though it did find potentially troubling prescribing practices.

Nuplazid, which hit the market in 2016, is the only medication approved to treat hallucinations and delusions associated with a debilitating condition known as Parkinson's disease psychosis. It has been cited as a "suspect" medication in hundreds of deaths voluntarily reported to the agency, as highlighted in a CNN report earlier this year.

Business and industry sectors

Business, economy and trade

Diseases and disorders

Government organizations - US

Health and medical

Neurological disorders and injuries

Parkinson's disease

Pharmaceutical industry

Pharmaceuticals and biotechnology

Pharmaceuticals and prescription drugs

US Department of Health and Human Services

US federal departments and agencies

US Food and Drug Administration

Medical experts told CNN at the time that the high number of so-called "adverse event reports" deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.

Nuplazid's initial review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.

After CNN published its investigation on Nuplazid, reporters were contacted by family members who said they believed the drug contributed to their loved one's decline or death. Others said Nuplazid helped tame hallucinations with few apparent side effects.

The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.

On Thursday, the FDA said it had completed a review of these deaths and other adverse events that had been reported to the agency.

"Overall, the postmarketing data were consistent with the safety data obtained from the premarketing controlled clinical trials of Nuplazid for Parkinson's disease psychosis," it stated.

Acadia Pharmaceuticals, the company that manufactures Nuplazid, welcomed the FDA findings. "Nothing is more important to Acadia than the wellbeing of the patients who use Nuplazid," Steve Davis, the company's president and chief executive officer, said in a statement. "We are very pleased with the FDA's clear statement reaffirming Nuplazid's positive benefit-risk profile."

Dr. Paul Andreason, the physician who led the FDA's initial medical review of Nuplazid, had warned at the time of Nuplazid's approval that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.

In its statement this week, the FDA noted that like other antipsychotics, the drug already has the agency's most severe "black box" warning about the increased risk of death for the treatment of elderly dementia patients.

The agency also said its review had found "potentially concerning prescribing patterns," such as the use of Nuplazid with other antipsychotic drugs or with medications that can cause heart issues. It urged health care providers to familiarize themselves with the warnings and precautions associated with Nuplazid when prescribing it to patients.

The FDA said it would continue to monitor reports of adverse events and encouraged patients and doctors to report any suspected side effects to the agency.

Do you have information to share about Nuplazid or other drugs targeting the elderly? Email us: watchdog@cnn.com.

This story has been updated with a statement from Acadia Pharmaceuticals.

Minnesota Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 139444

Reported Deaths: 2440
CountyConfirmedDeaths
Hennepin34988995
Ramsey14471364
Dakota10132138
Anoka9160153
Washington623372
Stearns608248
Scott354934
Olmsted335930
St. Louis314271
Wright265315
Clay246443
Nobles231918
Blue Earth20857
Carver18677
Kandiyohi17835
Sherburne176322
Rice168310
Mower153918
Winona129619
Chisago11142
Crow Wing108322
Benton10099
Lyon10076
Waseca9419
Beltrami9278
Otter Tail9217
Todd8726
Morrison8029
Steele7873
Polk7864
Itasca77117
Nicollet75618
Douglas7344
Freeborn7004
Le Sueur6516
Goodhue63311
Martin61918
McLeod6154
Becker6044
Isanti5835
Watonwan5814
Pine5630
Carlton4832
Chippewa4693
Mille Lacs43216
Hubbard4233
Cass4055
Dodge4050
Wabasha4050
Pipestone36117
Rock3555
Meeker3483
Brown3353
Roseau3000
Redwood29411
Yellow Medicine2946
Murray2913
Cottonwood2900
Fillmore2650
Renville26313
Sibley2623
Wadena2573
Faribault2440
Kanabec23010
Houston2201
Jackson2191
Swift2122
Pennington2091
Unassigned19553
Lincoln1910
Aitkin1882
Stevens1861
Koochiching1765
Pope1650
Big Stone1531
Lac qui Parle1453
Wilkin1424
Marshall1371
Lake1290
Clearwater1281
Mahnomen1282
Norman1280
Grant1024
Red Lake822
Traverse580
Kittson500
Lake of the Woods451
Cook180

Iowa Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 119931

Reported Deaths: 1677
CountyConfirmedDeaths
Polk19440289
Woodbury735998
Johnson596531
Black Hawk5862102
Linn5823132
Dubuque538358
Scott474442
Story408218
Dallas352547
Pottawattamie333245
Sioux249817
Buena Vista227912
Marshall209036
Webster192315
Plymouth170331
Wapello157362
Clinton151627
Muscatine151258
Des Moines147310
Cerro Gordo146127
Crawford137014
Warren12947
Carroll118913
Jasper115034
Henry10955
Marion104811
Tama98637
Lee98311
Delaware81713
Dickinson7769
Wright7481
Boone7369
Mahaska72824
Bremer7029
Harrison68415
Washington67711
Jackson6623
Benton6222
Lyon5598
Clay5474
Louisa53415
Winnebago50619
Winneshiek4969
Cedar4947
Hardin4887
Kossuth4850
Hamilton4794
Buchanan4755
Poweshiek47211
Jones4704
Clayton4613
Floyd45211
Emmet44620
Iowa4299
Page4190
Guthrie41315
Mills4133
Cass4123
Cherokee4112
Sac4074
Butler3963
Franklin39318
Shelby3932
Fayette3924
Allamakee3879
Madison3713
Chickasaw3691
Clarke3573
Humboldt3503
Hancock3394
Grundy3326
Palo Alto3262
Calhoun3234
Osceola2930
Mitchell2881
Howard2819
Monroe26411
Union2635
Taylor2522
Jefferson2471
Monona2472
Pocahontas2382
Appanoose2343
Fremont2121
Lucas2106
Ida2082
Adair1911
Greene1890
Montgomery1877
Davis1854
Van Buren1842
Keokuk1711
Decatur1600
Audubon1561
Worth1460
Wayne1343
Ringgold922
Adams841
Unassigned90
Rochester
Overcast
35° wxIcon
Hi: 36° Lo: 25°
Feels Like: 27°
Mason City
Overcast
36° wxIcon
Hi: 39° Lo: 26°
Feels Like: 27°
Albert Lea
Overcast
36° wxIcon
Hi: 36° Lo: 27°
Feels Like: 29°
Austin
Overcast
36° wxIcon
Hi: 37° Lo: 28°
Feels Like: 28°
Charles City
Overcast
39° wxIcon
Hi: 40° Lo: 27°
Feels Like: 30°
Tracking a breezy weekend
KIMT Radar
KIMT Eye in the sky

Community Events